Commonly used therapies to treat these cancers either target the ER directly through selective ER modulators and downregulators (SERMs and SERDs); or diminish endogenous estrogen levels via ovarian ablation or the use of aromatase inhibitors. This evidence concerns the gene ESR1 and cancer.